Forest Laboratories acquired by Actavis for $25B

02/19/2014 | Reuters · Genetic Engineering & Biotechnology News · Bloomberg

Generic-drug manufacturer Actavis agreed to pay approximately $25 billion, or $89.48 per share, to purchase Forest Laboratories in a cash-and-stock deal expected to be finalized by the middle of this year. The acquisition will combine the firms' growing specialty pharmaceutical portfolios and will give Actavis a major focus on higher-margin, brand-name drugs for Alzheimer's disease, high blood pressure and more. "With this strategic combination, we create an innovative new model in specialty pharmaceuticals leadership, with size and scale, a balanced offering of strong brands and generics," Actavis Chairman and CEO Paul Bisaro said.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News · Bloomberg

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD